Merck KGaA (MIL:1MRK) Cyclically Adjusted Revenue per Share: € (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1MRK Merck KGaA MIL:1MRK
81 GF Score
Price €129.65
GF Value €141.31
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Cyclically Adjusted Revenue per Share?

Merck KGaA MIL:1MRK -1.97% 81 Cyclically Adjusted Revenue per Share is € as of Jun. 2026. GuruFocus rates MIL:1MRK with a GF Score™ of 81/100 and a GF Value™ of €141.31 (Fairly Valued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Merck KGaA's adjusted revenue per share for the three months ended in Jun. 2026 was €12.498. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is for the trailing ten years ended in Jun. 2026.

During the past 12 months, Merck KGaA's average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Merck KGaA was 10.70% per year. The lowest was 5.40% per year. And the median was 8.40% per year.

As of today (2026-09-21), Merck KGaA's current stock price is €129.65. Merck KGaA's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was . Merck KGaA's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck KGaA was 6.46. The lowest was 2.15. And the median was 3.44.


Merck KGaA  (MIL:1MRK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck KGaA was 6.46. The lowest was 2.15. And the median was 3.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Merck KGaA Cyclically Adjusted Revenue per Share Related Terms


Merck KGaA Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Cyclically Adjusted Revenue per Share Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merck KGaA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MIL:1MRK vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck KGaA Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck KGaA's Cyclically Adjusted PS Ratio falls into.


MIL:1MRK
81GF Score
Merck KGaA MIL:1MRK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck KGaA's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=12.498/131.3638*131.3638
=12.498

Current CPI (Jun. 2026) = 131.3638.

Merck KGaA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 8.565 101.017 11.138
201612 8.809 101.217 11.433
201703 8.880 101.417 11.502
201706 8.499 102.117 10.933
201709 8.089 102.717 10.345
201712 8.390 102.617 10.740
201803 8.018 102.917 10.234
201806 8.542 104.017 10.788
201809 8.623 104.718 10.817
201812 8.941 104.217 11.270
201903 8.616 104.217 10.860
201906 9.133 105.718 11.349
201909 9.324 106.018 11.553
201912 10.076 105.818 12.509
202003 10.051 105.718 12.489
202006 9.474 106.618 11.673
202009 10.228 105.818 12.697
202012 10.576 105.518 13.167
202103 10.651 107.518 13.013
202106 11.201 108.486 13.563
202109 11.438 109.435 13.730
202112 11.990 110.384 14.269
202203 11.956 113.968 13.781
202206 12.807 115.760 14.533
202209 13.354 118.818 14.764
202212 13.018 119.345 14.329
202303 12.174 122.402 13.065
202306 12.195 123.140 13.009
202309 11.898 124.195 12.585
202312 12.018 123.773 12.755
202403 11.776 125.038 12.372
202406 12.310 125.882 12.846
202409 12.112 126.198 12.608
202412 12.462 127.041 12.886
202503 12.144 127.779 12.485
202506 12.087 128.412 12.365
202509 12.232 129.255 12.432
202512 12.073 129.361 12.260
202603 11.808 131.258 11.817
202606 12.498 131.364 12.498

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of € mean?
Merck KGaA (MIL:1MRK) has a Cyclically Adjusted Revenue per Share of € as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Cyclically Adjusted Revenue per Share too high?
Merck KGaA's current Cyclically Adjusted Revenue per Share is €. Overall, Merck KGaA has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Merck KGaA's Cyclically Adjusted Revenue per Share of € can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck KGaA and its competitors. Merck KGaA's current Cyclically Adjusted Revenue per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (MIL:1MRK) is currently considered Fairly Valued. The stock's GF Value™ is €141.31, compared to a current price of €129.65 — trading 8.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €. Merck KGaA's overall GF Score™ is 81/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Merck KGaA (MIL:1MRK), the current Cyclically Adjusted Revenue per Share is € as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (MIL:1MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of €129.65 is trading 8.3% below its estimated GF Value™ of €141.31. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for MIL:1MRK:

  • Cyclically Adjusted Revenue per Share:
  • GF Value™: €141.31 vs. price of €129.65 (8.3% below fair value)
  • GF Score™: 81/100 with 10 warning signs

No single metric tells the full story. See the MIL:1MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
81GF Score

Get the complete analysis for MIL:1MRK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€129.65
Price
€141.31
GF Value